文献速递炎症性肠病

瑞典60岁及以上人群炎症性肠病诊断的发病率与治疗

Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
PubMed 文献 · Gastroenterology · 2017-11-02

该研究基于瑞典全国登记数据,纳入2006至2013年27834例新发炎症性肠病(IBD)患者,其中6443例(23%)首次诊断年龄≥60岁,对应发病率为35/10万人年。老年患者较成人患者使用生物制剂和免疫调节剂更少、全身糖皮质激素更多,且5年肠手术绝对风险更高(13% vs 10%,P<.001),但相对风险增幅在年轻组更大。

要点

  • 瑞典2006-2013年新发IBD中23%(6443/27834)首次诊断于≥60岁,发病率35/10万人年。
  • 老年IBD患者较成人患者使用生物制剂和免疫调节剂更少,但全身糖皮质激素使用更多。
  • 老年患者5年肠手术率为13%,高于成人患者的10%(P<.001)。

核心结论

  • 在瑞典全国队列中,≥60岁诊断IBD与较少的生物制剂和免疫调节剂使用相关,但肠手术绝对风险高于较年轻诊断者。
  • 成人与老年患者药物治疗的巨大差异不一定反映疾病病程更轻,需进一步研究。

研究设计与样本

  • 全国性人群为基础的队列研究,利用瑞典国家登记数据识别2006年至2013年所有新发IBD病例,并为每例匹配最多10名人群对照。
  • 共纳入27834例新发IBD患者,其中6443例(23%)首次诊断年龄≥60岁。
  • 按发病年龄分组:儿童<18岁、成人18-59岁、老年≥60岁。
  • 中位随访4.2年(范围0-9年)。

主要发现

  • 老年患者IBD发病率35/10万人年,其中克罗恩病10/10万人年、溃疡性结肠炎19/10万人年、未分类IBD 5/10万人年。
  • 老年患者较成人患者IBD特异性门诊医疗更少,但IBD相关住院和总体医疗使用更多。
  • 老年患者较儿童或成人发病患者使用生物制剂和免疫调节剂更少,但全身糖皮质激素使用更多。
  • 肠外表现发生在老年与成人患者中相似,但肠手术在老年患者中更常见(5年后13% vs 成人10%,P<.001)。
  • 肠手术绝对风险老年高于一般人群,但相对风险增幅在较年轻年龄组更大。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Diagnosis of inflammatory bowel diseases (IBD) is increasing among elderly persons (60 years or older). We performed a nationwide population-based study to estimate incidence and treatment of IBD. METHODS: We identified all incident IBD cases in Sweden from 2006 through 2013 using national registers and up to 10 matched population comparator subjects. We collected data on the patients' health care contacts and estimated incidence rates, health service burden, pharmacologic treatments, extra-intestinal manifestations, and surgeries in relation to age of IBD onset (pediatric, <18 years; adults, 18-59 years; elderly, ≥60 years). RESULTS: Of 27,834 persons diagnosed with incident IBD, 6443 (23%) had a first diagnosis of IBD at 60 years or older, corresponding to an incidence rate of 35/100,000 person-years (10/100,000 person-years for Crohn's disease, 19/100,000 person-years for ulcerative colitis, and 5/100,000 person-years for IBD unclassified). During a median follow-up period of 4.2 years (range, 0-9 years), elderly patients had less IBD-specific outpatient health care but more IBD-related hospitalizations and overall health care use than adult patients with IBD. Compared with patients with pediatric or adult-onset IBD, elderly patients used fewer biologics and immunomodulators but more systemic corticosteroids. Occurrence of extra-intestinal manifestations was similar in elderly and adult patients, but bowel surgery was more common in the elderly (13% after 5 years vs 10% in adults) (P < .001). The absolute risk of bowel surgery was higher in the elderly than in the general population, but in relative terms, the risk increase was larger in younger age groups. CONCLUSIONS: In a nationwide cohort study in Sweden, we associated diagnosis of IBD at age 60 years or older with a lower use of biologics and immunomodulators but higher absolute risk of bowel surgery, compared with diagnosis at a younger age. The large differences in pharmacologic treatment of adults and elderly patients are not necessarily because of a milder course of disease and warrant further investigation.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Everhov ÅH, Halfvarson J, Myrelid P, et al. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden. Gastroenterology. 2017. PMID: 29102619. doi:10.1053/j.gastro.2017.10.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。